YZ-0217

YZ-0217 is a preclinical-stage small molecule inhibitor targeting the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway. Developed by Guangdong Yinzhu Pharmaceutical Technology, it is primarily being investigated for the treatment of multiple myeloma, specifically in combination with dexamethasone. The NF-κB pathway plays a pivotal role in the pathogenesis of multiple myeloma by promoting cell survival, proliferation, and resistance to apoptosis. By targeting this pathway, YZ-0217 aims to disrupt these oncogenic signals and enhance the therapeutic efficacy of standard treatments like dexamethasone.